Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.58 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.43 |
| ▸ | NMT2 | O60551 | 2/20 | 0.42 |
| ▸ | NMT1 | P30419 | 2/20 | 0.42 |
| ▸ | EPOR | P19235 | 2/20 | 0.41 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.40 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29329023 | 0.98 | GLP1R (0.56) | GLP1RFOLH1NMT2NMT1EPOR | |
| SCHEMBL24668378 | 0.98 | GLP1R (0.57) | GLP1RFOLH1NMT2NMT1EPOR | |
| SCHEMBL25269706 | 0.92 | GLP1R (0.58) | GLP1RFOLH1NMT2NMT1EPOR | |
| SCHEMBL25269707 | 0.92 | GLP1R (0.58) | GLP1RFOLH1NMT2NMT1EPOR | |
| SCHEMBL29336336 | 0.89 | GLP1R (0.66) | GLP1RFOLH1TLR2NOD1 | |
| SCHEMBL30094802 | 0.88 | GLP1R (0.59) | GLP1RNMT2NMT1SIRT6SIRT1 | |
| SCHEMBL29336162 | 0.87 | GLP1R (0.64) | GLP1RFOLH1NMT2NMT1EPOR | |
| SCHEMBL16328746 | 0.87 | GLP1R (0.51) | GLP1RNMT2NMT1SIRT6SIRT1 | |
| SCHEMBL24667763 | 0.85 | GLP1R (0.45) | GLP1RFOLH1EPORSIRT6SIRT1 | |
| SCHEMBL25132767 | 0.85 | GLP1R (0.56) | GLP1RNMT2NMT1SIRT6SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | ADAXION THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | FCGR3B, CD47, IL2 | GLP1R 2531/4885FOLH1 614/4885NMT2 2649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.